Thursday, September 24

7:00 p.m.-8:00 p.m. Opening Keynote Session
Ellington Ballroom
Session Chairperson: Charles W.M. Roberts, St. Jude Children’s Research Hospital, Memphis, TN

Welcome remarks
Charles W.M. Roberts

Keynote Address
Epigenetic mechanisms of tumor initiation and evolution
Bradley E. Bernstein, Massachusetts General Hospital, Harvard Medical School, Boston, MA

8:00 p.m.-9:30 p.m. Welcome Reception
Overlook

Friday, September 25

7:00 a.m.-8:00 a.m. Continental Breakfast
Terrace and Ellington Prefunction

8:00 a.m.-10:00 a.m. Plenary Session 1: Epigenetic Regulation of Transcription Initiation
Ellington Ballroom
Session Chairperson: Peter A. Jones, Van Andel Research Institute, Grand Rapids, MI

8:00 a.m. Genomic organization of yeast chromatin and gene regulatory complexes
B. Franklin Pugh, Penn State University, University Park, PA

8:30 a.m. Elucidating and targeting dichotomous roles of the PRC2 complex in cancer
Karen M. Cichowski, Brigham and Women’s Hospital, Boston, MA

9:00 a.m. How DNA methylation organizes the cancer epigenome
Peter A. Jones

9:30 a.m. Structural mechanism of sequence-specific 5-methylcytosine (5mC) recognition by AP-1 transcription factors*
Samuel Hong, Emory University, Atlanta, GA

9:45 a.m. Transcriptional regulation mediated by biochemically distinct forms of SWI/SNF*
Jesse R. Raab, University of North Carolina at Chapel Hill, Chapel Hill, NC

*Short talks from proffered papers
10:00 a.m.-10:30 a.m.  Break
Ellington Prefunction

10:30 a.m.-12:30 p.m.  Plenary Session 2: Enhancers, Epigenetics, and Cancer
Ellington Ballroom
Session Chairperson: Charles W.M. Roberts, St. Jude Children’s Research Hospital, Memphis, TN

10:30 a.m.  Genome-wide views into the mechanisms of transcription regulation
John T. Lis, Cornell University, Ithaca, NY

11:00 a.m.  SWI/SNF chromatin remodeling complex mutations in cancer: Mechanisms and potential therapeutic insights
Charles W.M. Roberts

11:30 a.m.  Decoding the cancer regulome
John Stamatoyannopoulos, University of Washington, Seattle, WA

12:00 p.m.  Exploring the link between Kras and histone acetylation*
Alessandro Carrer, Abramson Family Cancer Research Institute, Philadelphia, PA

12:15 p.m.  Targeting super-enhancer driven oncogene transcription through cyclin-dependent kinase inhibitors*
Rani E. George, Dana-Farber Cancer Institute, Boston, MA

12:30 p.m.-2:30 p.m.  Poster Session A with Lunch
Overlook

2:30 p.m.-4:30 p.m.  Plenary Session 3: Control of Transcription and Elongation
Ellington Ballroom
Session Chairperson: Karen Adelman, Laboratory of Epigenetics and Stem Cell Biology, National Institute of Environmental Health Sciences, Research Triangle Park, NC

2:30 p.m.  An epigenome perspective of human tumor evolution
Joseph F. Costello, UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, CA

3:00 p.m.  Nucleosome barriers to transcription
Steven Henikoff, Fred Hutchinson Cancer Research Center, Seattle, WA

3:30 p.m.  Regulating transcription elongation at stimulus responsive genes
Karen Adelman

4:00 p.m.  Using epigenetic profiling and CRISPR screens to understand cancer progression
X. Shirley Liu, Dana-Farber Cancer Institute, Boston, MA

4:30 p.m.-  Evening on Own

*Short talks from proffered papers
Saturday, September 26

7:00 a.m.-8:00 a.m.  Continental Breakfast
Terrace and Ellington Prefunction

8:00 a.m.-10:00 a.m.  Plenary Session 4: Chromatin Organization
Ellington Ballroom
Session Chairperson: Sharon Y.R. Dent, The University of Texas MD Anderson Cancer Center, Smithville, TX

8:00 a.m.  Long-range gene regulation in the context of chromatin domains
Job Dekker, University of Massachusetts Medical School, Worcester, MA

8:30 a.m.  Structure and function of BAF complexes in human cancer
Cigall Kadoch, Dana-Farber Cancer Institute, Boston, MA

9:00 a.m.  A SAGA of GCN5 and USP22 in development and disease
Sharon Y.R. Dent

9:30 a.m.  Mechanisms of ATP-dependent chromatin remodeling
Geeta Narlikar, University of California at San Francisco, San Francisco, CA

10:00 a.m.-10:30 a.m.  Break
Ellington Prefunction

10:30 a.m.-12:30 p.m.  Plenary Session 5: ncRNAs and Cancer
Ellington Ballroom
Session Chairperson: Ramin Shiekhattar, University of Miami Miller School of Medicine, Miami, FL

10:30 a.m.  The impact of cohesin mutations in tumor initiation: One ring, many functions
Iannis Aifantis, HHMI/NYU School of Medicine, New York, NY

11:00 a.m.  Biogenesis and mechanism of action of enhancer RNAs
Ramin Shiekhattar

11:30 a.m.  Functional characterization of the tumor suppressor lysine-specific methyltransferase KMT2D in lymphoma
Hans-Guido Wendel, Memorial Sloan Kettering Cancer Center, New York, NY

12:00 p.m.  “Viral mimicry” as a mechanism of action for DNA-demethylating agents*
Daniel De Carvalho, Princess Margaret Cancer Centre, Toronto, ON, Canada

12:15 p.m.  Analysis of enhancer transcription reveals novel gene regulatory networks in breast cancer*
Hector L. Franco, The Cecil H. and Ida Green Center for Reproductive Biology Sciences, UT Southwestern Medical Center, Dallas, TX

12:30 p.m.-2:30 p.m.  Lunch on own/Free Time

*Short talks from proffered papers
2:30 p.m.-4:30 p.m.  Plenary Session 6: Cancer Genomics and Epigenomics
Ellington Ballroom
Session Chairperson: Suzanne J. Baker, St. Jude Children’s Research Hospital, Memphis, TN

2:30 p.m.  Integrative epigenomic analysis across cancer types
Peter W. Laird, Van Andel Research Institute, Grand Rapids, MI

3:00 p.m.  The oncogenic role of histone H3 mutations in pediatric high-grade gliomas
Suzanne J. Baker

3:30 p.m.  The cell-type specific effect of epigenomic features on cancer mutation
Shamil Sunyaev, Brigham and Women’s Hospital, Harvard Medical School, Boston, MA

4:00 p.m.  The oncogenic BRD4-NUT chromatin regulator drives aberrant transcription within large topological domains*
Erica M. Walsh, Brigham and Women’s Hospital, Harvard Medical School, Boston, MA

4:15 p.m.  GC skew defines distinct RNA polymerase pause sites in CpG island promoters*
Joshua S.K. Bell, Emory University, Atlanta, GA

4:30 p.m.-6:30 p.m.  Poster Session B and Reception
Overlook

6:30 p.m.-   Evening on Own

*Short talks from proffered papers
Sunday, September 27

7:00 a.m.-8:00 a.m. Continental Breakfast
Terrace and Ellington Prefunction

8:00 a.m.-10:00 a.m. Plenary Session 7: Epigenetic Cancer Therapies 1
Ellington Ballroom
Session Chairperson: Stephen B. Baylin, Johns Hopkins University School of Medicine, Baltimore, MD

8:00 a.m. Targeting DNA methylation abnormalities as a cancer therapy strategy
Stephen B. Baylin

8:30 a.m. Multiple targetable pathways for epigenetic therapy
Jean-Pierre Issa, Fels Institute for Cancer Research and Molecular Biology, Temple University, Philadelphia, PA

9:00 a.m. Discovery of novel epigenetic targets
Frank Stegmeier, Novartis, Cambridge, MA

9:30 a.m. EZH2 inhibitors reveal broad EZH2 dependencies in multiple myeloma*
Shilipi Arora, Constellation Pharmaceuticals, Cambridge, MA
This talk is not accredited for CME credit to permit the free flow of information of the commercial interest employees participating.

9:45 a.m. A DNA hypomethylation signature predicts novel anti-tumor activity of LSD1 inhibition in SCLC*
Helai Mohammad, GlaxoSmithKline, Collegeville, PA
This talk is not accredited for CME credit to permit the free flow of information of the commercial interest employees participating.

10:00 a.m.-10:15 a.m. Break
Ellington Prefunction

*Short talks from proffered papers
10:15 a.m.-12:15 p.m.  **Plenary Session 8: Epigenetic Cancer Therapies 2**  
Ellington Ballroom  
*Session Chairperson: Ari M. Melnick, Weill Cornell Medical College of Cornell University, New York, NY*

10:15 a.m.  **Epigenetics switches enabling transformation of B cells**  
Ari M. Melnick

10:45 a.m.  **Next-generation bromodomain inhibitors**  
James E. Bradner, Dana-Farber Cancer Institute, Boston, MA

11:15 a.m.  **Tazemetostat, an EZH2 Inhibitor and potential therapeutic for non-Hodgkin lymphoma**  
Jesse J. Smith, Epizyme, Inc., Waltham, MA

11:45 a.m.  **A bromodomain cassette exchange strategy establishes that on-target chemical inhibition of BRD9 limits leukemia cell proliferation**  
*Anja F. Hohmann, Cold Spring Harbor Laboratory, Cold Spring Harbor, NY*

12:00 p.m.  **MED12 methylation by CARM1 sensitizes human breast cancer cells to chemotherapy drugs**  
*Wei Xu, University of Wisconsin, Madison, WI*

*Short talks from proffered papers*